drugset / Trial / NCT02192099
Open Label Extension for GLYX13-C-202, NCT01684163
NaSingle-groupOpen-labelTreatment
Summary
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
Timeline
- Start
- 2014-09-08
- Primary completion
- 2018-11-08
- Completion
- 2018-11-08
Outcome
Outcome not reported
Stopped: “Patients from this study were rolled into RAP-MD-99.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rapastinel | Other / unclassified | 225 mg | Intravenous |
| Subject | Rapastinel | Other / unclassified | 450 mg | Intravenous |